Figure 3.

Change from baseline in sleep latency for each of the five individual trials in the Maintenance of Wakefulness Test (MWT) at Week 12 (modified intent-to-treat population). Individual MWT trials, each of 40-minute duration, were performed at 2-hour intervals beginning 2 hours after awakening and 1 hour after dosing at the approximate times postdose shown in parentheses. The result at trial 4 for 37.5 mg was of nominal significance based on the prespecified testing sequence. *P < 0.05 and ^†P < 0.0001 versus placebo.